GlassScriptPhysician profile
Janet Hernandez
NPI 1417407826
$6,362.05
in general payments reported to CMS, 2019-2025
29 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.45 · 2022: $1,872 · 2023: $1,625 · 2024: $546 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,242 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.28 |
| Education | $175.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,715.10 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $740.05 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $653.15 | 2022-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $566.64 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $323.00 | 2022-2025 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $306.76 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $304.89 | 2023-2025 | Livdelzi |
| Ardelyx, INC. | $297.15 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $265.18 | 2022-2025 | Ocaliva |
| Pfizer INC. | $219.17 | 2025 | |
| Phathom Pharmaceuticals, INC. | $166.01 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $130.37 | 2022-2023 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $120.64 | 2023 | Zeposia |
| Genzyme Corporation | $94.43 | 2025 | |
| Braintree Laboratories, INC. | $76.94 | 2022-2023 | Sutab, Suflave |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $76.90 | 2022 | |
| Evoke Pharma, INC. | $34.57 | 2023 | Gimoti |
| Nestle Healthcare Nutrition INC. | $34.18 | 2021 | |
| Merck Sharp & Dohme LLC | $30.17 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $27.57 | 2023 | Bylvay |
| Emd Serono, INC. | $26.19 | 2021 | |
| Sandoz INC. | $25.00 | 2024 | |
| Novo Nordisk INC | $23.99 | 2025 | Wegovy |
| Cumberland Pharmaceuticals, INC. | $20.33 | 2022 | |
| Csl Behring | $19.23 | 2022 | |
| Qol Medical, LLC | $18.81 | 2024 | Sucraid |
| Fresenius Kabi USA, LLC | $17.87 | 2024 | Idacio |
| Abbott Laboratories | $16.68 | 2025 | Cardiomems |
| Avion Pharmaceuticals | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.